ProPhase (PRPH): Fair Value Consensus

The price trend visualization for ProPhase Labs, Inc. (PRPH) confirms the resilience of a business protected by patents and stringent CLIA requirements. ProPhase Labs, Inc. (PRPH) revenues are based on the volume of diagnostic procedures and the sale of dietary supplements, with the indicator standing at 159.40. The company generates profit by serving the US public sector and private clinics, offering high-tech genetic tests. The primary focus is on the margins of its own brands and the rapid processing of genomic information.

This indicator aggregates the expected market value of the asset, reflecting the valuation's sensitivity to future cash flows and business growth rates. For ProPhase Labs, Inc. (PRPH), the consensus target price will serve as a leading indicator of the efficiency of its transition to genomics, as a reversal of the line will confirm that the company has overcome costs associated with underutilized capacity and restored its operating leverage.